Bulletin
Investor Alert

New York Markets Open in:

press release

Aug. 12, 2021, 7:45 a.m. EDT

Harrow Health to Participate in Two Upcoming Virtual Investor Conferences

NASHVILLE, Tenn., (BUSINESS WIRE) -- Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW -3.18% , an ophthalmic-focused healthcare company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Financial Officer, will participate in two upcoming virtual investor conferences.

  • Harrow Health will participate in the H.C. Wainwright Ophthalmology Virtual Conference to be held August 17, 2021. The Company’s pre-recorded presentation will be available via a link on the investor relations section of its website, harrowinc.com , beginning at 7:00 a.m. ET on Tuesday, August 17, 2021, and will remain archived there for approximately 90 days. Harrow Health’s management team will be participating in one‘on-one meetings during the conference. Interested investors can request meetings exclusively via H.C. Wainwright.

  • The Company will also be attending Lake Street Capital Market’s 5 [th] Annual Best Ideas Growth Conference (BIG5) on September 15, 2021. Management will be available throughout the day for one-on-one meetings with investors to provide an update on the Company’s business. Investors should contact their Lake Street representative to arrange a meeting or request an invitation.

About Harrow Health

Harrow Health, Inc. /zigman2/quotes/206805265/composite HROW -3.18% is an ophthalmic-focused healthcare company. The Company owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical businesses, and Visionology, a direct-to-consumer eye care subsidiary focused on chronic eye disease. Harrow Health also holds non-controlling equity positions in Eton Pharmaceuticals, Surface Ophthalmics and Melt Pharmaceuticals, all of which started as Harrow Health subsidiaries, and owns royalty rights in four clinical-stage drug candidates being developed by Surface Ophthalmics and Melt Pharmaceuticals. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005137/en/

SOURCE: Harrow Health, Inc.

Jamie Webb
Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

COMTEX_391444795/2456/2021-08-12T07:45:16

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2021

/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 9.73
-0.32 -3.18%
Volume: 42,973
Oct. 21, 2021 4:00p
P/E Ratio
37.28
Dividend Yield
N/A
Market Cap
$270.28 million
Rev. per Employee
$390,968
loading...
/zigman2/quotes/206805265/composite
US : U.S.: Nasdaq
$ 9.73
-0.32 -3.18%
Volume: 42,973
Oct. 21, 2021 4:00p
P/E Ratio
37.28
Dividend Yield
N/A
Market Cap
$270.28 million
Rev. per Employee
$390,968
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.